Overview

An Investigation Into the Short Term Effect of APOMINE in Patients With Osteoporosis or Low Bone Mass

Status:
Terminated
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
Osteoporosis affects millions of postmenopausal women in the USA. The current approved treatments are all drugs that prevent bone loss and possibly result in small gains in bone mass. Another possible treatment consists of drugs that increase bone formation. There are currently two drugs that stimulate bone formation, sodium fluoride and human parathyroid hormone (hPTH). Neither of these two drugs has been approved by the FDA. APOMINE has shown significant bone formation in animal studies. In this study we plan to test whether APOMINE is able to stimulate new bone formation in women with osteoporosis or low bone mass.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Genzyme, a Sanofi Company
Treatments:
Diphosphonates